Sparks commentary

Healthcare

Sparks

Isofol (ST: ISOFOL) commences Phase Ib/II arfolitixorin trial
Published by Arron Aatkar, PhD

Isofol has announced that the first patient has been included in the Phase Ib/II trial of arfolitixorin in metastatic colorectal cancer. The trial has been designed to assess the drug candidate as part of the standard 5-FU-based first-line therapy for the condition. The trial is being conducted in two stages. The initial Phase Ib part will evaluate the risk/benefit profile of escalating doses in a new dosing regimen. The second part of the trial will compare the highest dose from Phase Ib with one of the lower doses, with efficacy parameters as primary endpoints.